The Latest Breaking News from BristolMyers Squibb

Bristol-Myers Squibb (NYSE:BMY) has observed the following analyst ratings within the last quarter:

May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month, bringing the total for the year to 15. This compares to the 24 NMEs the Food and…

Someone with a lot of money to spend has taken a bearish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Bristol-Myers Squibb's (NYSE:BMY) short percent of float has fallen 10.76% since its last report. The company recently reported that it has 42.24 million shares sold short, which is 1.99% of all regular shares that are available for trading.

Warren Buffett is arguably the world’s most famous investor, and his investment moves are closely followed. Each quarter, the company he runs, Berkshire Hathaway, discloses its current holdings to shareholders.

A whale with a lot of money to spend has taken a noticeably bullish stance on Bristol-Myers Squibb. Looking at options history for Bristol-Myers Squibb (NYSE:BMY) we detected 14 strange trades.

Bristol-Myers Squibb's (NYSE:BMY) short percent of float has fallen 8.23% since its last report. The company recently reported that it has 47.34 million shares sold short, which is 2.23% of all regular shares that are available for trading.

Someone with a lot of money to spend has taken a bullish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

According to Benzinga Pro, during Q1, Bristol-Myers Squibb (NYSE:BMY) earned $1.28 billion, a 45.91% increase from the preceding quarter. Bristol-Myers Squibb's sales decreased to $11.65 billion, a 2.81% change since Q4.

Bristol-Myers Squibb (NYSE:BMY) has observed the following analyst ratings within the last quarter:

Someone with a lot of money to spend has taken a bearish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.